ELISA Kit for Anti-Lecithin Cholesterol Acyltransferase Antibody (Anti-LCAT) 
phosphatidylcholine-sterol O-acyltransferase; Phospholipid-cholesterol acyltransferase
- UOM
- FOB US$ 560.00 US$ 800.00 US$ 3,600.00 US$ 6,800.00 US$ 56,000.00
- Quantity
Overview
Properties
- Product No.AEJ516Hu
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- ApplicationsEnzyme-linked immunosorbent assay for Antibody Detection.
Research use only - DownloadInstruction Manual
- CategoryEnzyme & Kinase
Sign into your account
Share a new citation as an author
Upload your experimental result
Review
Contact us
Please fill in the blank.
-
Packages (Simulation)
-
Packages (Simulation)
-
Results demonstration
-
Typical Standard Curve
-
ISO9001: 2008, ISO13485: 2003 Registered
Recovery
Matrices listed below were spiked with certain level of Anti-Lecithin Cholesterol Acyltransferase Antibody (Anti-LCAT) and the recovery rates were calculated by comparing the measured value to the expected amount of Anti-Lecithin Cholesterol Acyltransferase Antibody (Anti-LCAT) in samples.
| Matrix | Recovery range (%) | Average(%) |
| serum(n=5) | 78-98 | 90 |
| EDTA plasma(n=5) | 93-101 | 97 |
| heparin plasma(n=5) | 80-94 | 83 |
Precision
Intra-assay Precision (Precision within an assay): 3 samples with low, middle and high level Anti-Lecithin Cholesterol Acyltransferase Antibody (Anti-LCAT) were tested 20 times on one plate, respectively.
Inter-assay Precision (Precision between assays): 3 samples with low, middle and high level Anti-Lecithin Cholesterol Acyltransferase Antibody (Anti-LCAT) were tested on 3 different plates, 8 replicates in each plate.
CV(%) = SD/meanX100
Intra-Assay: CV<10%
Inter-Assay: CV<12%
Linearity
The linearity of the kit was assayed by testing samples spiked with appropriate concentration of Anti-Lecithin Cholesterol Acyltransferase Antibody (Anti-LCAT) and their serial dilutions. The results were demonstrated by the percentage of calculated concentration to the expected.
| Sample | 1:2 | 1:4 | 1:8 | 1:16 |
| serum(n=5) | 89-96% | 83-97% | 78-94% | 78-94% |
| EDTA plasma(n=5) | 96-103% | 97-105% | 98-105% | 80-105% |
| heparin plasma(n=5) | 95-104% | 93-105% | 99-105% | 85-103% |
Stability
The stability of kit is determined by the loss rate of activity. The loss rate of this kit is less than 5% within the expiration date under appropriate storage condition.
To minimize extra influence on the performance, operation procedures and lab conditions, especially room temperature, air humidity, incubator temperature should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same operator from the beginning to the end.
Reagents and materials provided
| Reagents | Quantity | Reagents | Quantity |
| Pre-coated, ready to use 96-well strip plate | 1 | Plate sealer for 96 wells | 4 |
| Standard | 2 | Standard Diluent | 1×20mL |
| Detection Reagent A | 1×120µL | Assay Diluent A | 1×12mL |
| TMB Substrate | 1×9mL | Stop Solution | 1×6mL |
| Wash Buffer (30 × concentrate) | 1×20mL | Instruction manual | 1 |
Assay procedure summary
1. Prepare all reagents, samples and standards;
2. Add 100µL standard or sample to each well. Incubate 1 hours at 37°C;
3. Aspirate and add 100µL prepared Detection Reagent A. Incubate 1 hour at 37°C;
4. Aspirate and wash 5 times;
5. Add 90µL Substrate Solution. Incubate 10-20 minutes at 37°C;
6. Add 50µL Stop Solution. Read at 450nm immediately.
Test principle
The microtiter plate provided in this kit has been pre-coated with LCAT. Standards or samples are then added to the appropriate microtiter plate wells with a Horseradish Peroxidase (HRP)-conjugated secondary antibody. After TMB substrate solution is added, those wells that contain Anti-LCAT will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulphuric acid solution and the color change is measured spectrophotometrically at a wavelength of 450nm ± 10nm. The concentration of Anti-LCAT in the samples is then determined by comparing the O.D. of the samples to the standard curve.
Giveaways
Increment services
Citations
- Plasma phospholipase, γ‐CEHC and antioxidant capacity in fibromyalgiaPubMed: 26585319
- Alteration of Lysophosphatidylcholine-Related Metabolic Parameters in the Plasma of Mice withExperimental Sepsis.pubmed:28028754
- A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours.pubmed:28664912
- Lipid-lowering effects of medium-chain triglyceride-enriched coconut oil in combination with licorice extracts in experimental hyperlipidemic micePubmed: 30244576
- Identification and validation of differentially expressed proteins in serum of CSU patients with different duration of wheals using an iTRAQ labeling, 2D‑LC‑MS/MSDoi: 10.3892/etm.2018.6818
- Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel.Pubmed: 31388184
- The synergistic mechanism of total saponins and flavonoids in Notoginseng− Safflower pair against myocardial ischemia uncovered by an integrated …Pubmed: 32739736
- Pharmacokinetics/pharmacometabolomics-pharmacodynamics reveals the synergistic mechanism of a multicomponent herbal formula, Baoyuan decoction?¡
- Defects in a liver-bone axis contribute to hepatic osteodystrophy disease progressionPubmed:35235775